IDEXX Laboratories Delivers Strong Q3 Results, Raises Full‑Year Guidance, Stock Soars

IDEXX Laboratories (Nasdaq: IDXX) reported third‑quarter 2026 financial results that surpassed expectations, with 10% year‑over‑year revenue growth (both reported and organic) to $1.214 billion. Earnings per diluted share came in at $4.01, up 18% as reported and 22% on a comparable basis. The company also lifted its full‑year guidance, fueling a surge in its stock price by approximately 21.9%. (Earnings from Business Wire; stock movement reported by Kiplinger)

The revenue gains reflected broad strength across IDEXX’s segments. Companion Animal Group (CAG) diagnostics recurring revenue grew 11% (both reported and organic), driven by strong instrument utilization, net new customer gains, and benefits from recent product rollouts. VetLab consumables grew 14% reported and 15% organic. Reference laboratory services increased 10%, while rapid assay products rose modestly at 1%. Capital instrument revenue was flat, supported by the placement of over 1,900 inVue Dx analyzers, bringing the installed base to nearly 11,000. (Business Wire)

Performance was also solid in Water and Livestock, Poultry and Dairy (LPD) segments: Water testing revenue rose 8% organically, and LPD revenue grew 3% organically in the quarter. (Business Wire)

Raised 2026 Outlook Supports Bullish Sentiment

In response to the strong quarterly performance, IDEXX raised its full‑year 2026 revenue guidance to a range of $4.741 billion to $4.767 billion—$32 million higher at the midpoint than prior guidance—with reported growth expected between 10.1% and 10.8%. Organic revenue growth is now expected at 9.3% to 10.0%. The company also raised its EPS outlook to a range of $14.96‑$15.16, versus the previous midpoint, reflecting both revenue strength and acquisition impacts. (Business Wire)

Gross profit for the quarter climbed 12% to approximately $764 million, with a gross margin of 62.9%, up 110 basis points. Operating margin also expanded by 100 basis points to 33.1%, supported by efficiency initiatives and pricing gains. (Business Wire)

Market Reaction and Analyst Response

IDEXX stock surged roughly 21.9% following the earnings release, making it one of the top gainers in the S&P 500. (Kiplinger)

Analysts responded positively: UBS raised its price target from $627 to $700 with a Neutral rating, Jefferies lifted its target to $770 (Buy), and Morgan Stanley raised its target to $810 (Overweight). (TipRanks)

Why It Matters

IDEXX’s Q3 results highlight the company’s ability to deliver across geographies and product segments amid softer broader veterinary clinic traffic. Strong diagnostic consumption and product innovation—such as in‑clinic analyzer placements—point to continued momentum. The upward guidance revision and bullish analyst reactions signal confidence in sustained growth heading into 2027.

Investors will watch for continued adoption of IDEXX’s innovations, pipeline expansion, and execution of its CAG diagnostics strategy—especially as operational and pricing pressures evolve. With the raised outlook backed by solid fundamentals and investor optimism, IDEXX is well‑positioned for upside potential.